NHSBSA Secondary Care Medicines Data (SCMD)
Medicines issued by NHS hospital trusts in England (England only: acute, teaching, specialist, mental health and community trusts), from the NHS Business Services Authority's Secondary Care Medicines Data (SCMD) on the NHSBSA Open Data Portal: monthly quantities of every dm+d Virtual Medicinal Product (VMP) issued by each trust from April 2019, with an indicative cost (list or reimbursement price, not the confidential price trusts paid). Finds a medicine by part of its product name or its VMP SNOMED code over up to 24 months, finalised months where NHSBSA has published them and provisional ones after, and totals it by product, by trust (with the trust's name from NHS England's ODS directory) or by month. Hospital issues only, not community prescribing. Open Government Licence v3.0; every answer carries NHSBSA's attribution and the cost caveat.
Try NHSBSA Secondary Care Medicines Data (SCMD) now.
Choose an example or ask your own question.
const result = await firecrawl.scrape({
alexandria: {
provider: "opendata-nhsbsa-net",
capability: "hospital-medicines/search",
options: {
from: "2025-01",
medicine: "pembrolizumab",
to: "2025-12",
},
},
});This is a sample shape. Press Run to see live data from NHSBSA Secondary Care Medicines Data (SCMD).
{
"cost_caveat": "Indicative cost is a list or reimbursement price, not what trusts paid. NHSBSA: \"Actual costs cannot be displayed in the dataset as NHS Hospital pricing contracts and NICE Patient Access Schemes are confidential.\" It uses community pharmacy reimbursement prices for generic medicines and list prices for branded medicines, and \"does not reflect the net actual cost of NHS Trusts, which will differ due to the application of confidential discounts, rebates, or procurement agreements paid by hospitals when purchasing medicines.\" A null cost means NHSBSA holds no price for the product, not zero.",
"from": "2025-01",
"group_by": "product",
"license": {
"attribution": "Source: NHS Business Services Authority (NHSBSA), Secondary Care Medicines Data (SCMD) with indicative price, published on behalf of NHS England. Contains public sector information licensed under the Open Government Licence v3.0.",
"name": "Open Government Licence v3.0",
"trust_names_attribution": null,
"url": "https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/"
},
"medicine": {
"match": "product_name_contains",
"query": "pembrolizumab"
},
"months": [
{
"dataset": "finalised",
"month": "2025-01",
"resource": "SCMD_FINAL_202501",
"unit_dose_reported": false,
"url": "https://opendata.nhsbsa.net/dataset/finalised-secondary-care-medicines-data-scmd-with-indicative-price/resource/5cde935b-17b6-4c6e-a2a5-bb40d0270288"
},
{
"dataset": "finalised",
"month": "2025-02",
"resource": "SCMD_FINAL_202502",
"unit_dose_reported": false,
"url": "https://opendata.nhsbsa.net/dataset/finalised-secondary-care-medicines-data-scmd-with-indicative-price/resource/b416af4e-fbb4-4bdf-92dc-a784947393ec"
},
{
"dataset": "finalised",
"month": "2025-03",
"resource": "SCMD_FINAL_202503",
"unit_dose_reported": false,
"url": "https://opendata.nhsbsa.net/dataset/finalised-secondary-care-medicines-data-scmd-with-indicative-price/resource/480e886c-0546-4f97-8e24-d134235b29ef"
},
{
"dataset": "finalised",
"month": "2025-04",
"resource": "SCMD_FINAL_202504",
"unit_dose_reported": false,
"url": "https://opendata.nhsbsa.net/dataset/finalised-secondary-care-medicines-data-scmd-with-indicative-price/resource/a10a727b-acfe-41bd-9a29-21f63c1f592b"
},
{
"dataset": "finalised",
"month": "2025-05",
"resource": "SCMD_FINAL_202505",
"unit_dose_reported": false,
"url": "https://opendata.nhsbsa.net/dataset/finalised-secondary-care-medicines-data-scmd-with-indicative-price/resource/3fe15b41-19dd-49f4-9a80-e268a9f5a40c"
},
{
"dataset": "finalised",
"month": "2025-06",
"resource": "SCMD_FINAL_202506",
"unit_dose_reported": false,
"url": "https://opendata.nhsbsa.net/dataset/finalised-secondary-care-medicines-data-scmd-with-indicative-price/resource/820d8017-4d2c-4df3-b185-7d78f7e07471"
},
{
"dataset": "finalised",
"month": "2025-07",
"resource": "SCMD_FINAL_202507",
"unit_dose_reported": false,
"url": "https://opendata.nhsbsa.net/dataset/finalised-secondary-care-medicines-data-scmd-with-indicative-price/resource/8ab7b0a8-9eaa-424c-a575-cd576e4beecd"
},
{
"dataset": "finalised",
"month": "2025-08",
"resource": "SCMD_FINAL_202508",
"unit_dose_reported": false,
"url": "https://opendata.nhsbsa.net/dataset/finalised-secondary-care-medicines-data-scmd-with-indicative-price/resource/bcb0933f-88d1-429e-9ee4-3a26b29b06cd"
},
{
"dataset": "finalised",
"month": "2025-09",
"resource": "SCMD_FINAL_202509",
"unit_dose_reported": false,
"url": "https://opendata.nhsbsa.net/dataset/finalised-secondary-care-medicines-data-scmd-with-indicative-price/resource/7c7718b2-5e8a-4224-b102-bb649a7d4a32"
},
{
"dataset": "finalised",
"month": "2025-10",
"resource": "SCMD_FINAL_202510",
"unit_dose_reported": false,
"url": "https://opendata.nhsbsa.net/dataset/finalised-secondary-care-medicines-data-scmd-with-indicative-price/resource/0d39f680-5bc3-4ff0-8fe8-684734d1a990"
},
{
"dataset": "finalised",
"month": "2025-11",
"resource": "SCMD_FINAL_202511",
"unit_dose_reported": false,
"url": "https://opendata.nhsbsa.net/dataset/finalised-secondary-care-medicines-data-scmd-with-indicative-price/resource/fd047985-d084-4d01-81df-08a75fc9a8bd"
},
{
"dataset": "finalised",
"month": "2025-12",
"resource": "SCMD_FINAL_202512",
"unit_dose_reported": false,
"url": "https://opendata.nhsbsa.net/dataset/finalised-secondary-care-medicines-data-scmd-with-indicative-price/resource/a767f48b-b7c4-4609-ab74-6230ddc68f82"
}
],
"months_unavailable": [],
"results": [
{
"indicative_cost_gbp": 546677520.25,
"product_name": "Pembrolizumab 100mg/4ml solution for infusion vials",
"quantity": 831448.7,
"trusts": 104,
"unit": "ML",
"unit_dose_quantity": null,
"unit_dose_unit": null,
"unpriced_rows": 0,
"vmp_snomed_code": "34378411000001105"
},
{
"indicative_cost_gbp": 3337338.5,
"product_name": "Pembrolizumab 50mg powder for solution for infusion vials",
"quantity": 2537.9,
"trusts": 2,
"unit": "VIAL",
"unit_dose_quantity": null,
"unit_dose_unit": null,
"unpriced_rows": 0,
"vmp_snomed_code": "30033011000001108"
},
{
"indicative_cost_gbp": null,
"product_name": "Pembrolizumab 200mg/100ml in Sodium chloride 0.9% infusion bags",
"quantity": 3383100,
"trusts": 57,
"unit": "ML",
"unit_dose_quantity": null,
"unit_dose_unit": null,
"unpriced_rows": 571,
"vmp_snomed_code": "44064111000001104"
},
{
"indicative_cost_gbp": null,
"product_name": "Pembrolizumab 400mg/100ml in Sodium chloride 0.9% infusion bags",
"quantity": 1672699.5,
"trusts": 50,
"unit": "ML",
"unit_dose_quantity": null,
"unit_dose_unit": null,
"unpriced_rows": 466,
"vmp_snomed_code": "44065011000001101"
},
{
"indicative_cost_gbp": null,
"product_name": "Pembrolizumab 100mg/50ml in Sodium chloride 0.9% infusion bags",
"quantity": 300,
"trusts": 1,
"unit": "ML",
"unit_dose_quantity": null,
"unit_dose_unit": null,
"unpriced_rows": 5,
"vmp_snomed_code": "44061311000001100"
},
{
"indicative_cost_gbp": null,
"product_name": "Pembrolizumab 150mg/100ml in Sodium chloride 0.9% infusion bags",
"quantity": 100,
"trusts": 1,
"unit": "ML",
"unit_dose_quantity": null,
"unit_dose_unit": null,
"unpriced_rows": 1,
"vmp_snomed_code": "44062511000001103"
}
],
"source_updated_at": "2026-08-25",
"source_url": "https://opendata.nhsbsa.net/dataset/finalised-secondary-care-medicines-data-scmd-with-indicative-price",
"to": "2025-12",
"total_count": 6,
"totals": {
"indicative_cost_gbp": 550014858.75,
"products": 6,
"rows": 2141,
"trusts": 107,
"unpriced_rows": 1043
},
"warnings": [
{
"code": "unpriced_rows",
"message": "1043 of 2141 matched rows have no indicative cost because NHSBSA holds no price for the product; their cost is null, never 0, and indicative_cost_gbp sums only priced rows."
}
]
}Source: NHS Business Services Authority (NHSBSA), Secondary Care Medicines Data (SCMD) with indicative price, published on behalf of NHS England. Contains public sector information licensed under the Open Government Licence v3.0. (https://opendata.nhsbsa.net/pages/terms-and-conditions)